MORRISVILLE, North Carolina, January 9, 2017 /PRNewswire/ --
Barbara Zupancic, Director of Global Patient Recruitment and Retention at Worldwide Clinical Trials, will present at this year's Summit for Clinical Operations Executives (SCOPE), being held Jan. 24-26 at the Hyatt Regency in Miami, FL.
Zupancic will discuss her observations in patient recruitment, retention and engagement in Alzheimer's Disease during her presentation, titled "Patient Recruitment of Alzheimer's Disease: Using Behavioral Research to Create Lasting Engagement and Trial Success," which will be held on Thursday, Jan. 26 at 9:55 a.m. ET.
"We face many challenges when undertaking Alzheimer's Disease research, not the least of which is patient recruitment and retention," comments Zupancic. "It is essential to develop and implement a patient-centered strategy for enrollment and outreach planning, which can lead to faster recruitment and lasting engagement."
In addition to Zupancic's presentation, experts from the Worldwide Clinical Trials team will also be on hand at the company's booth (#706) to discuss the challenges and opportunities in the design and implementation of clinical trials across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases.
The annual SCOPE Summit offers three days of discussion, conferences and workshops covering all aspects of clinical trial planning and management. To schedule an appointment with a Worldwide expert at SCOPE, visit http://www.worldwide.com/events. For further information about SCOPE, visit http://www.scopesummit.com .
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit http://www.Worldwide.com .
SOURCE Worldwide Clinical Trials